Brief: Hansa Biopharma Announces Positive Full Results From 15-Hmedides-09 Phase 2 Study And Comparative Analysis Of Imlifidase In Patients With Guillain-Barré Syndrome
17/12/2024 22:21
Dec 17 (Reuters) - Hansa Biopharma AB HNSA.ST :
* HANSA BIOPHARMA ANNOUNCES POSITIVE FULL RESULTS FROM
15-HMEDIDES-09 PHASE 2 STUDY AND COMPARATIVE ANALYSIS OF
IMLIFIDASE IN PATIENTS WITH GUILLAIN-BARRÉ SYNDROME
Source text: ID:nPrexgxX1a
Further company coverage: HNSA.ST
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Hansa Biopharma AB
See all newsBrief: Hansa Biopharma Q3 Rev Up At SEK 143 Mln
Sweden's Hansa Biopharma Q3 revenue surges on SERB license deal
Brief: Hansa Biopharma Q3 Net Income SEK -178.5 Million
Brief: Hansa Biopharma Announces Positive Idefirix Paes Results Presented In The High-Impact Clinical Trials Session At Asn Kidney Week
Brief: Hansa Biopharma Submits IND Application To FDA For HNSA-5487 In GBS